NCT02658396View on ClinicalTrials.gov

GO-203-2C + Bortezomib For Relapsed Or Refractory MM

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

Not specified

Primary Completion Date

May 31, 2019

Study Completion Date

January 31, 2022

Conditions

Multiple MyelomaMultiple Myeloma in RelapseRefractory Multiple Myeloma

Interventions

DRUG

GO-203-2C

DRUG

Bortezomib

Trial Locations (2)

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

Genus Oncology, LLC

All Listed Sponsors

collaborator

Genus Oncology, LLC

INDUSTRY

collaborator

National Institutes of Health (NIH)

NIH

lead

Dana-Farber Cancer Institute

OTHER